Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Feb 16:12:42.
doi: 10.1186/1471-2334-12-42.

Comparative activity of carbapenem testing (the COMPACT study) in Turkey

Hakan Leblebicioglu  1 , Nedim Cakir, Mustafa Celen, Halil Kurt, Hakan Baris, Joerg Laeuffer; Turkish COMPACT Study Group
Collaborators, Affiliations
Comparative Study

Comparative activity of carbapenem testing (the COMPACT study) in Turkey

Hakan Leblebicioglu et al. BMC Infect Dis. .

Abstract

Background: Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey.

Methods: Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing.

Results: Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, ≥ 64, and ≥ 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and ≥ 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.

Conclusions: Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative% minimum inhibitory concentration (MIC) distributions against Pseudomonas aeruginosa (N = 293).
Figure 2
Figure 2
Cumulative% minimum inhibitory concentration (MIC) distributions against Enterobacteriaceae (N = 240).
Figure 3
Figure 3
Cumulative% minimum inhibitory concentration (MIC) distributions against Acinetobacter baumannii (N = 53).
See this image and copyright information in PMC

References

    1. Health Protection Agency: Surveillance of healthcare associated infections report. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1216193833496
    1. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis. 2009;63:217–222. doi: 10.1016/j.diagmicrobio.2008.11.004. - DOI - PubMed
    1. Gur D, Korten V, Unal S, Deshpande LM, Castanheira M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol. 2008;57:1529–1532. doi: 10.1099/jmm.0.2008/002469-0. - DOI - PubMed
    1. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 2004;54:144–154. doi: 10.1093/jac/dkh298. - DOI - PubMed
    1. Doribax. Annex I. Summary of product characteristics. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info...

Publication types

MeSH terms